Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time
- 1 March 2021
- journal article
- review article
- Published by Elsevier in Trends in Microbiology
- Vol. 29 (3) , 195-203
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
This publication has 41 references indexed in Scilit:
- mRNA mediates passive vaccination against infectious agents, toxins, and tumorsEMBO Molecular Medicine, 2017
- Germinal Center B Cell DynamicsImmunity, 2016
- Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricinJournal of Controlled Release, 2016
- SARS and MERS: recent insights into emerging coronavirusesNature Reviews Microbiology, 2016
- Nanobody-based products as research and diagnostic toolsTrends in Biotechnology, 2014
- Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpuraBlood, 2012
- Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugsBlood, 2011
- Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcriptionThe International Journal of Biochemistry & Cell Biology, 2009
- Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodiesProceedings of the National Academy of Sciences, 2006
- Naturally occurring antibodies devoid of light chainsNature, 1993